tigecycline Side Effects
Also known as: Tygacil
Analysis of 5,878 adverse event reports submitted to the FDA from 2005 to 2025.
Total Reports
5,878
Death-Related
1,597
27.2% of reports
Hospitalizations
2,363
40.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,597 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 387 |
| DEATH | 252 |
| SEPTIC SHOCK | 176 |
| OFF LABEL USE | 160 |
| SEPSIS | 160 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 98 |
| THROMBOCYTOPENIA | 92 |
| PATHOGEN RESISTANCE | 85 |
| MULTI-ORGAN FAILURE | 76 |
| TREATMENT FAILURE | 75 |
| PNEUMONIA | 70 |
| CONDITION AGGRAVATED | 65 |
| DRUG RESISTANCE | 60 |
| KLEBSIELLA INFECTION | 58 |
| RESPIRATORY FAILURE | 58 |
| HYPOTENSION | 57 |
| NEUTROPENIA | 50 |
| RENAL FAILURE | 49 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 47 |
| ACUTE KIDNEY INJURY | 45 |
Reactions in Hospitalization Reports
Top reactions in 2,363 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 306 |
| OFF LABEL USE | 266 |
| THROMBOCYTOPENIA | 156 |
| NAUSEA | 149 |
| SEPSIS | 139 |
| SEPTIC SHOCK | 119 |
| VOMITING | 118 |
| DIARRHOEA | 112 |
| PYREXIA | 103 |
| PANCREATITIS ACUTE | 95 |
| PNEUMONIA | 85 |
| ACUTE KIDNEY INJURY | 82 |
| CONDITION AGGRAVATED | 80 |
| PANCREATITIS | 76 |
| DRUG RESISTANCE | 72 |
| HYPOTENSION | 72 |
| PATHOGEN RESISTANCE | 72 |
| ANAEMIA | 71 |
| COAGULOPATHY | 71 |
| DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS | 71 |
Nearby — Related Medications
What the FAERS Data Reveals About tigecycline Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 5,878 voluntary reports linked to tigecycline and its brand equivalents (Tygacil), spanning 2005 through 2025. Of those, 1,597 (27.2%) listed death as an outcome and 2,363 (40.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 43% were female and 56% male; age distribution skews toward 45-64, with 1,376 reports in that bracket. The single most reported reaction is drug ineffective with 720 submissions, followed by off label use and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.